The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
REGULATORY
Japan Begins Discussions on RSV Vaccines for National Immunization Program
The Japanese government on March 14 kicked off discussions on the potential inclusion of respiratory syncytial virus (RSV) vaccines in its national immunization program, or NIP. A health ministry panel will deliberate on their NIP addition for both older adults…
To read the full story
Related Article
- Cost-Effectiveness Talks Continue on Expanding HPV Vaccinations to Males
September 26, 2025
- Japan to Prepare Fact Sheets on RSV Vaccine, Antibody
September 5, 2024
- No Inclusion of Males in National HPV Vaccinations for Now: MHLW Panel
May 23, 2024
REGULATORY
- Japan Weighs Scrapping “Spillover” Rule in Shift from Draft Reform Outline
December 24, 2025
- Heparinoid, Allergy Drugs among OTC-Like Meds Up for Special Charge Rule
December 24, 2025
- Japan Approves Batch of New Drugs, Subcutaneous Rybrevant Finally Cleared
December 23, 2025
- Japan, Spain Move to Deepen Pharmaceutical Regulatory Cooperation
December 23, 2025
- Japan Drops Transitional Plan for PCV20 Routine Shot in Elderly
December 23, 2025
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…